| Name | Title | Contact Details |
|---|
Since its founding in 2005, Dramatic Health has stood at the forefront of high quality healthcare video production, and the online/mobile distribution of those assets.
At Transitions Optical we help people live more vibrant lives by enhancing their vision and the way they perceive light. We were the first to successfully commercialise a plastic photochromic lens in 1990 and our talented people continue to make significant advances in colour science and lens materials, creating a better photochromic experience that`s available to more people. Through our partnerships with optical industry leaders, we offer adaptive solutions in the widest selection of designs and materials, covering hundreds of lens combinations. Our industry leading eyeglass brands are well known; Transitions® Signature®, Transitions® Vantage® and Transitions® XTRActive®. And we don`t stop there; we also make adaptive sunwear and motorcycle helmet shields. Transitions Optical is part of the Essilor Group.
Insitu Technologies Inc is a Saint Paul, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
GCG Communications is a Reston, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.